key: cord-1048625-p893n9ew
authors: van Gils, M. J.; Lavell, A. H. A.; van der Straten, K.; Appelman, B.; Bontjer, I.; Poniman, M.; Burger, J. A.; Oomen, M.; Bouhuijs, J. H.; van Vught, L. A.; Slim, M. A.; Schinkel, M.; Wynberg, E.; van Willigen, H. D. G.; Grobben, M.; Tejjani, K.; Snitselaar, J. L.; Caniels, T. G.; Vlaar, A. P. J.; Prins, M.; de Jong, M. D.; de Bree, G.; Sikkens, J. J.; Bomers, M. K.; Sanders, R. W.
title: Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
date: 2021-09-28
journal: nan
DOI: 10.1101/2021.09.27.21264163
sha: aee25717e40dba0b3bca392ebd8dccccf7613f87
doc_id: 1048625
cord_uid: p893n9ew

Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. We performed a head-to-head comparison of the ability of sera from individuals vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S) to recognize and neutralize the four SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma and Delta). Four weeks after completing the vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (median titers of 1891 and 3061, respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median titers of 241 and 119, respectively). VOCs neutralization was reduced in all vaccine groups, with the largest (5.8-fold) reduction in neutralization being observed against the Beta variant. Overall, the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after the final vaccination.

As of September 2021, the coronavirus disease 2019 (COVID-19) pandemic has caused over 220 million confirmed infections and over 4.5 million reported deaths 1 , calling for strong interventions. A number of vaccines have been developed that proved efficacious in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of COVID-19, and/or severe disease from infection, providing hope that we can halt this pandemic. Three vaccines, i.e. those developed by Pfizer-BioNTech (BNT162b2/Comirnaty), Moderna (mRNA-1273/Spikevax) and J&J/Janssen (Ad26.COV2.S), have been approved (for emergency use) in the United States by the FDA, while the EMA in the European Union has additionally approved (for emergency use) a fourth vaccine from Oxford/AstraZeneca (AZD1222/Vaxzevria). Early efficacy trials showed that the mRNA vaccines BNT162b2 and mRNA-1273 had high efficacy (>90%) against symptomatic infection, whereas the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S resulted in lower vaccine efficacy (60-70%) against symptomatic infection [2] [3] [4] [5] . However, all four vaccines were extremely effective at preventing severe disease. Neutralizing antibodies proved to be a very strong correlate of protection [6] [7] [8] . So far, over five billion COVID-19 vaccine doses have already been administered worldwide 1 .

Since the start of the pandemic, SARS-CoV-2 has diversified considerably, both genetically and antigenically. Four virus lineages are currently designated as a variant of concern (VOC) by the WHO due to, among others, suspected increased transmissibility or In field trials, several vaccines proved less efficacious against VOCs, in particular the Beta 4, 8, [11] [12] [13] [14] [15] [16] . In fact, the Oxford/AstraZeneca vaccine was virtually ineffective in preventing . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 18 , in particular after a single vaccine dose. In line with these observations, VOCs were shown to be less sensitive to neutralizing antibodies induced by infection or vaccination. Antibody responses are generally sufficient to neutralize the Alpha variant to similar levels as the original Wuhan strain in mRNA vaccine recipients and in convalescent individuals. However, the Beta, Gamma and Delta variants showed on average an 8.8-fold, 3.5-fold and 3.9-fold reduced sensitivity to neutralization by sera from convalescent patients as well as from vaccine recipients 8 .

Although previous studies have provided valuable initial insights in the sensitivity of VOCs to neutralization induced by infection or vaccination, few studies have directly compared the ability of humoral responses induced by the different vaccines to cope with VOCs. Previous studies have used diverse serological assays, mainly focused on one or two vaccines, or used regression models to combine studies, complicating direct comparisons.

Here, we present a head-to-head comparison of the binding and neutralizing activity against all four VOCs in the serum of individuals who received the BNT162b2, mRNA-1273, AZD1222 or Ad.COV2.S vaccine.

In a direct head-to-head comparison, using the same assays, we assessed the ability of four FDA and/or EMA approved SARS-CoV-2 vaccines to induce humoral immune responses in humans. From the S3 cohort, which consists of Amsterdam UMC health care workers (HCWs) 19 , we included SARS-CoV-2 naive individuals who completed BNT162b2 (n=50), mRNA-1273 (n=40), AZD1222 (n=41) or Ad26.COV2.S vaccination (n=13 ; Table S1 ).

Although the four vaccine groups were fairly similar in composition; 62-87% female with the majority between 35-60 years old (Table 1) , the AZD1222 group mostly consists of individuals over 60 years of age, because the Dutch government restricted the use of AZD1222 to this age group due to safety concerns. Furthermore, the Ad26.COV2.S group included fewer individuals because the Dutch government temporarily restricted its use because of similar reasons 20 . For vaccinees who received the BNT162b2, mRNA-1273 and AZD122 vaccines, samples were taken three weeks after the first vaccination and four weeks after the second . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint 5 vaccination (Fig. 1A) . As the Ad26.COV2.S vaccine uses a single-dose regime, vaccine recipients were sampled approximately five and eight weeks after the single-dose vaccination.

We first assessed S protein binding titers in vaccinee sera after complete vaccination in a custom luminex assay against the wild-type (WT) S protein from the Wuhan Hu-1 virus (GenBank: MN908947.3) isolated in December 2019, i.e. the same S protein sequence as was used in the four vaccines 21 . Overall, the antibody responses against the S protein were relatively homogeneous within each group, showing larger intergroup than intragroup difference, with only one Ad26.COV2.S recipient having binding titers below the limit of detection after complete vaccination (Fig. 1B, Table S2 ). Antibody responses in fully vaccinated mRNA-1273 and BNT162b2 recipients were comparable with convalescent individuals 4-6 weeks after symptom onset (COSCA study, n = 68) (median MFI titers of 1482 and 1257 versus 1382, respectively), but the responses of AZD1222 and Ad26.COV2.S recipients were substantially (17 to 29-fold) lower (median MFI of 74 and 52, respectively).

Next, we tested the neutralizing activity of vaccinee sera using a lentiviral-based pseudovirus assay of the SARS-CoV-2 D614G (B.1) variant (Fig. 1C , Table S2 ). We detected the highest neutralization activity in recipients of mRNA-1273 and BNT162b2 (median ID50 titers of 3061 and 1891, respectively), and approximately an order of magnitude lower activity in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median ID50 titers of 241 and 119, respectively), with 1/50 BNT162b2, 7/30 AZD1222 and 6/13 Ad26.COV2.S recipients having undetectable neutralization activity (half-maximal neutralization titer, ID50 < 100) (Fig. 1C , Table S2 ). The differences in humoral immune responses between the groups following vaccination are consistent with the observed differences in the efficacy of these vaccines and in agreement with the observations that neutralizing antibodies are a strong correlate of protection [6] [7] [8] .

We also assessed the responses after one vaccination with each of the four vaccines.

First, we wished to directly compare the single-dose of Ad26.COV2.S with one dose of each of the other three vaccines. Second, we wanted to gauge the level of humoral immunity after partial vaccination, which is relevant when vaccinating during an infection wave and/or when considering to postpone the second vaccination.

All BNT162b2 and mRNA-1273 recipients had detectable antibody binding titers against S after one vaccination, while 5 out of 42 AZD1222 and 1 of 13 Ad26.COV2.S recipients did not (Fig. 1B) . The binding antibody titers were highest for the mRNA vaccine is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. 

We generated pre-fusion stabilized S proteins from all four VOCs (i.e. Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1 and Delta/B.1.617.2; Table S3 ) for use in our custom luminex assay.

After full vaccination, the binding antibody responses against VOCs S proteins were similar to those against WT S protein ( Fig. 2A , S1A, Table S2 ) as was the ranking of the different vaccines. Thus, mRNA vaccine recipients had higher binding responses compared to adenovirus vector-based vaccine recipients for all VOCs.

We next tested the neutralizing activity of the vaccine sera against the four VOCs ( Fig.   2B , S1B, Table S2 ). The neutralizing titers were highest in the mRNA recipients (median ID50 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. (Table S3) . As sera quantities were limited, we tested these viruses against pooled sera from each vaccine group, as well as pooled sera from two convalescent cohorts, the COSCA and RECOVERED 22, 23 . Since most Ad26.COV2.S recipients had undetectable neutralizing ability against VOC's, these sera were not included in this analysis.

We also included the four VOCs in this analysis and found that the neutralization ID50 values obtained with the pooled sera were highly concordant with the median ID50 values of the individual sera, indicating that the pooling of sera yields representable results. The set of pooled sera had diverse neutralization titers against the VOCs and VOIs (Fig. 3) . In particular, the Beta, and Kappa variants showed reduced sensitivity to neutralization, confirming previously observed fold reductions (Fig. S3B) 8, 10 . The rank order between the different vaccines was consistent between the various VOCs and VOIs. The additional E484K mutation in the Alpha variant caused an additional 2.8-fold reduction in neutralization for all pools, corroborating the impact of this single RBD mutation on neutralization. The Beta, Gamma, Iota and Zeta variants have this mutation, while the Kappa variant has the E484Q mutation, contributing to their reduced sensitivity. The differences observed between these VOCs and VOIs indicate that other mutations in addition to E484K/Q, such as the K417T/N and L452R/Q . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. After one vaccine dose, we observed higher neutralization titers for mRNA-1273 recipients compared to the individuals receiving BNT162b2. Another study also reported that mRNA-1273 was slightly more efficient at inducing neutralizing antibodies compared to Our results on monoclonal antibodies, as well as many previous studies, identify the main culprits among the mutations present in VOCs and VOIs for reducing neutralization sensitivity. As RBD antibodies dominate the neutralizing antibody response, RBD mutations proved critical. E484K (present in Beta and Gamma) abrogates sensitivity to a number of RBD antibodies, while L452R (present in Delta) and K417N/T (present in Beta and Gamma) affect other subsets of RBD antibodies 10, 25, 42 . Several therapeutic antibodies currently in use for COVID-19 treatment are affected by these mutations and have reduced activity against VOCs 43 . The accumulation of these mutations, as well as others, in the context of a heavily mutated lab-built version of the Delta variant, renders Delta profoundly more resistant to neutralization 44 . Whether, when and how SARS-CoV-2 will evolve into such a resistant form will remain to be seen.

There are several limitations of our study. First, our study includes substantially more female than male participants, reflecting the gender distribution among HCW at our institute.

Second, the age distribution in the four groups is not identical. In particular, the AZD1222 group is, on average, considerably older as a consequence of restrictive use of the AZD1222 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint vaccine in individuals aged 60-64 years in the Netherlands. As immune responses tend to become weaker with higher age, this is a relevant factor when considering the weaker responses in the AZD1222 group. Finally, the samples we tested were taken at the expected peak of immunity. It will be relevant to study the durability of the neutralizing antibody responses after vaccination with each of these vaccines. Some studies suggest that immunity induced by adenovirus vaccines might be more durable than immunity from mRNA vaccines 8, 45 .

We have only analyzed known VOCs and VOIs and cannot predict how our results apply to future variants. One consideration is that current VOCs were probably selected based on increased fitness and/or transmissibility, while future variants may very well be selected based on escape from immunity when more and more people are vaccinated or have experienced COVD-19. Such escape variants may be more resistant to neutralizing antibodies induced by current vaccines than the VOCs and VOIs studied here and may render vaccines even less effective at preventing infection. However, while circulating antibodies might be unable to neutralize such emerging viruses, memory B cells are still likely to recognize them and undergo new rounds of affinity maturation, resulting in new neutralizing antibodies that should kick-in in time to prevent severe disease after infection.

Since March 2020 we followed a cohort of HCW in the Amsterdam University Medical Centers, consisting of two tertiary care hospitals 19 . Participants underwent frequent phlebotomies to determine seroconversion against SARS-CoV-2, measured by total Ig against S1-RBD using enzyme-linked immunosorbent assay (Wantai ELISA). In January 2021 seronegative HCW who received two doses of BNT162b2 with an interval of three weeks were included. From March till May 2021 another group of HCW was included who received the first dose of either mRNA-1273 or AZD1222, or a single dose Ad.26CoV2.S. The second dose of mRNA-1273 or AZD1222 was administered four weeks or six to twelve weeks after the first, respectively (Fig. 1A) . Blood samples were taken approximately three weeks after the first vaccine with BNT162b2, mRNA-1273 and AZD1222 and four weeks after the second vaccine. In the case of vaccination with Ad.26CoV2.S, blood samples were taken approximately four to five and eight weeks after vaccination (Fig. 1A) . Preferably a blood sample was taken within days before the first vaccine was administered. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint These include hospitalized and non-hospitalized participants and serum was obtained four to six weeks after symptom onset 22 . A serum pool was created from COSCA samples of 68 participants. Another serum pool was created from sera collected in the RECoVERED cohort 23 .

In total, 251 RECoVERED serum samples were used, obtained up to seven months post start of symptoms (median of 3 months) from participants who experienced mild, moderate or severe COVID-19. The S3 study, the COSCA study and the RECoVERED study were approved by the medical ethical review board of the Amsterdam University Medical Centers (NL73478.029.20, NL73281.018.20 and NL73759.018.20, respectively). All participants provided written informed consent.

The S constructs contained the following mutations compared to the WT variant (Wuhan Hu- vector containing a hexahistidine (his) tag with Gibson Assembly (ThermoFisher) 22 . All S constructs were verified by Sanger sequencing and subsequently produced in HEK293F cells (ThermoFisher) and purified as previously described 22 .

To measure the binding of IgG to the spike proteins of different VOCs, we covalently coupled pre-fusion stabilized spike proteins to Luminex Magplex beads using a two-step carbodiimide reaction as previously described 47 . In short, Luminex Magplex beads (Luminex) were washed with 100 mM monobasic sodium phosphate pH 6.2 and activated by addition of Sulfo-N-Hydroxysulfosuccinimide (Thermo Fisher Scientific) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (Thermo Fisher Scientific) and incubated for 30 min on a rotator at room temperature. After washing the activated beads three times with 50 mM MES pH 5.0, the spike proteins were added in ratio of 75 µg protein to 12.5 million beads and incubated for three hours on a rotator at room temperature. To block the beads for aspecific binding, we incubated the beads for 30minutes with PBS containing 2% BSA, 3% fetal calf serum and 0.02% Tween- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint 12 20 at pH 7.0. Finally, the beads were washed and stored at 4°C in PBS containing 0.05% sodium azide.

Optimization experiments determined the optimal concentration of the sera for studying the humoral vaccination response to be 100.000-fold dilution. As previously described 47 

The WT, D614G, Alpha, Alpha E484K, Beta and Gamma pseudovirus S constructs were ordered as gBlock gene fragments (Integrated DNA Technologies) and cloned using SacI and ApaI in the pCR3 SARS-CoV-2-SΔ19 expression plasmid 48 

Neutralization activity was tested using a pseudovirus neutralization assay, as previously described 22 . Shortly, HEK293T/ACE2 cells, kindly provided by Dr. Paul Bieniasz 48 , were . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint 13 seeded at a density of 20,000 cells/well in a 96-well plate coated with 50 μg/mL poly-L-lysine one day prior to the start of the neutralization assay. NAbs (1-50 μg/mL) or heat-inactivated sera samples (1:100 dilution) were serially diluted in cell culture medium (DMEM (Gibco), supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 μg/mL) and GlutaMax (Gibco)), mixed in a 1:1 ratio with pseudovirus and incubated for 1 hour at 37°C. Subsequently, these mixtures were added to the cells in a 1:1 ratio and incubated for 48 hours at 37°C, followed by a PBS wash and lysis buffer to measure the luciferase activity in cell lysates using the Nano-Glo Luciferase Assay System (Promega) and GloMax system (Turner BioSystems).

Relative luminescence units (RLU) were normalized to the positive control wells where cells were infected with pseudovirus in the absence of NAbs or sera. The inhibitory concentration (IC50) and neutralization titers (ID50) were determined as the NAb concentration and serum dilution at which infectivity was inhibited by 50%, respectively, using a non-linear regression curve fit (GraphPad Prism software version 8.3). Samples with ID50 titers < 100 were defined as having undetectable neutralization.

Data visualization and statistical analyses were performed in GraphPad Prism software is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

No competing interests.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in

Evidence for antibody as a protective correlate for COVID-19 vaccines

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

SARS-CoV-2 variants: levels of neutralisation required for protective immunity

SARS-CoV-2 variants, spike mutations and immune escape

Pandemic moves and countermoves: vaccines and viral variants

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 . CC-BY-NC-ND 4.0 International license Infection Among Hospital Health Care Workers

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination

Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

The effect of spike mutations on SARS-CoV-2 neutralization

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Interim Results of a Phase 1-2a Trial of Ad26

Virus vaccines: proteins prefer prolines

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

SARS-CoV-2 variants of concern partially escape humoral but not Tcell responses in COVID-19 convalescent donors and vaccinees

SARS-CoV-2-specific T cells in infection and vaccination

Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum

Saliva SARS-CoV-2 Antibody Prevalence in Children

Measuring SARS-CoV-2 neutralizing antibody activity using

All data are available in the main text or supplementary materials. Reagents used in this study are available upon reasonable request under an MTA with Amsterdam UMC. It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 28, 2021. ;  https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.27.21264163 doi: medRxiv preprint